Earnings summaries and quarterly performance for Caris Life Sciences.
Executive leadership at Caris Life Sciences.
Board of directors at Caris Life Sciences.
Research analysts covering Caris Life Sciences.
Recent press releases and 8-K filings for CAI.
Caris Life Sciences Reports Record Q3 2025 Revenue and Raises Full-Year Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported record Q3 2025 total revenues of $216.8 million, an increase of 113% year-over-year, driven by clinical profiling services revenue of $207.6 million, up 121% year-over-year.
- The company achieved significant profitability, with positive adjusted EBITDA of $51.2 million, net income of $24.3 million, and positive free cash flow of $55.3 million. Gross margins improved to 68%, up from 43.7% in Q3 2024.
- Clinical case volumes grew 18.2% year-over-year to slightly less than 51,000 profiles, and the average selling price (ASP) per profile increased 87% year-over-year to $4,089, including a $37.9 million revenue true-up.
- Caris raised its full-year 2025 total revenue guidance to $720 million-$730 million, representing a 75%-77% increase over 2024, and increased its clinical therapy selection volume growth expectation to 21%-22%.
- The Achieve One early detection study is complete with 3,000 subjects, and the Achieve Two study is well underway with over 15,600 patients enrolled, with Achieve One results expected in the first half of next year.
Nov 5, 2025, 9:30 PM
CAI Announces Strong Q3 2025 Financial Results and Updated Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- CAI reported Total Revenue of $216.8 million for Q3 2025, marking a 113% increase year-over-year.
- The company achieved Positive Adjusted EBITDA of $51.2 million and GAAP Net Income of $24.3 million in Q3 2025.
- Gross margin expanded to 68%, an improvement of approximately 2,432 basis points year-over-year.
- Clinical volume increased by 18% to 50,763 clinical cases, and Clinical ASP improved by 87% to $4,089 in Q3 2025.
- CAI updated its full-year 2025 Total Revenue guidance to $720 million – $730 million, projecting 75-77% year-over-year growth.
Nov 5, 2025, 9:30 PM
Caris Life Sciences Reports Strong Q3 2025 Results and Raises Full-Year Revenue Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported total revenue of $216.8 million for the third quarter of 2025, an increase of 113.4% over the corresponding prior year period.
- The company achieved net income of $24.3 million and positive Adjusted EBITDA of $51.2 million for Q3 2025.
- Caris Life Sciences reported positive net cash flow from operating activities of $62.4 million for the quarter ended September 30, 2025.
- The company raised its full-year 2025 revenue guidance to a range of $720 to $730 million, representing year-over-year growth of 75% to 77%.
Nov 5, 2025, 9:17 PM
Caris Life Sciences Reports Strong Q3 2025 Results and Raises Full-Year Guidance
CAI
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Caris Life Sciences reported Q3 2025 total revenue of $216.8 million, an increase of 113.4% over the corresponding prior year period.
- The company achieved net income of $24.3 million and positive Adjusted EBITDA of $51.2 million for Q3 2025.
- Clinical therapy selection cases grew 18.2% to 50,763, contributing to a gross margin of 68.0%.
- Caris Life Sciences generated positive net cash flow from operating activities of $62.4 million and positive free cash flow of $55.3 million in Q3 2025.
- The company raised its full-year 2025 revenue guidance to a range of $720 million to $730 million, representing 75% to 77% year-over-year growth.
Nov 5, 2025, 9:05 PM
Quarterly earnings call transcripts for Caris Life Sciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Caris Life Sciences's earnings for you
Get instant analysis when filings drop